ClinicalTrials.gg
CompletedNCT05852340Updated Oct 16, 2024Results posted

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

A Phase 1 interventional study of Ritlecitinib in Healthy Volunteers, Adult and Pharmacokinetics, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare if two forms of study medicine, Ritlecitinib, get processed differently in healthy adults.

This study is seeking participants who are:

  • aged 18 or older;
  • male or female who are healthy as determined by medical assessment ;
  • Body-mass Index (BMI) of 16 to 32, and a total body weight > 45kg.

The study will take up to 2.5 months, including the screening period. There will be 5 periods in total for this study. Participants will have to stay at the study clinic for at least 11 days. Participants will take Riltecitinib either as sprinkled in Soft Food or as Intact Blend-In Capsule. On day 1 of each period, participants will take Riltecitinib and have blood samples taken both before and afterwards. Participants will also answer questions for taste assessment purpose. A follow-up phone call will be made at 28 to 35 days after the last study period.

Read the detailed description

Ritlecitinib is a covalent and irreversible inhibitor of JAK3 with high selectivity over the other JAK isoforms (JAK1, JAK2, and TYK2). Ritlecitinib also inhibits irreversibly the tyrosine kinase expressed in TEC family kinases with selectivity over the broader human kinome. Treatment with ritlecitinib is expected to inhibit the inflammatory pathways mediated by IL 7, IL 15 and IL 21, all implicated in UC, CD, AA, RA, and vitiligo. Moreover, due to lack of activity against the other JAK isoforms, ritlecitinib is expected to spare immunoregulatory cytokines such as IL 10, IL 27 and IL 35, which are critical to the maintenance of immunosuppressive functions and immune homeostasis.

The objective of this study is to estimate the impact of administration methods on the bioavailability of the pediatric ritlecitinib intact BiC formulation. The study will be conducted as a Phase 1, open-label, single dose, randomized, 4-crossover periods and 1-fixed period design in a single cohort of approximately 12 healthy male or female participants at a single center. Participants will be randomized into 1 of 4 sequences of treatment. Blood samples will be collected for PK analysis. A taste assessment will be also conducted.

Participants will participate in the study for up to approximately 2.5 months, with the inclusion of the screening and follow-up period. On Day 1 of each period, participants will receive a single dose of IP. Administration of IP will be via dosing using intact BiCs with water or by emptying the capsule contents on soft food as per dosing instructions.

Participants will be confined in the CRU for a total of at least 11 days and discharged at the discretion of the investigator. A follow-up phone call will be made at least 28 calendar days and up to 35 calendar days after the last administration of the study intervention to capture any potential AE and confirm appropriate contraceptive usage.

Tolerability and safety will be assessed for all treatments by monitoring AEs.

02

Conditions studied

  • Healthy Volunteers
  • Adult
  • Pharmacokinetics

Keywords

  • Adult
  • Pharmacokinetic
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Aged 18 or older.
  2. Male or female who are healthy as determined by medical assessment.
  3. Body-mass Index () of 16 to 32, and a total body weight > 45kg.

Key Exclusion Criteria:

  1. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  2. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  3. Known immunodeficiency disorder, including positive serology for , or a first degree relative with a hereditary immunodeficiency, or infections (acute or chronic).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Treatment A

    ritlecitinib 1 x 30 milligram (mg) intact blend-in-capsule (BiC) in fasted state

    Drug: Ritlecitinib

  • Active comparator
    Treatment B

    contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on strawberry jam in fasted state

    Drug: Ritlecitinib

  • Active comparator
    Treatment C

    contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on yoghurt in fasted state

    Drug: Ritlecitinib

  • Active comparator
    Treatment D

    contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on applesauce in fasted state

    Drug: Ritlecitinib

  • Active comparator
    Treatment E

    ritlecitinib 1 x 30 mg intact BiC given with high fat meal

    Drug: Ritlecitinib

Interventions

  • ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E) ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)

    Also known as: PF-06651600

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib

    AUCinf was defined as area under the plasma-concentration time profile from time zero extrapolated to infinite time. AUCinf for ritlecitinib was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose on Day 1 of each period. Each treatment period lasted 24 hours. Dosing of each period was separated by at least a 48-hour washout interval.

  2. Maximum Observed Concentration (Cmax) of Ritlecitinib

    Cmax was defined as maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose on Day 1 of each period. Each treatment period lasted 24 hours. Dosing of each period was separated by at least a 48-hour washout interval.

Secondary outcomes

  1. Number of Participants With All-Causality and Treatment-Related Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were events between first dose of study treatment and up to approximately 35 days that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days)

  2. Number of Participants With Laboratory Abnormalities

    Hematology included hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet and white blood cell count, total neutrophils, eosinophils, etc. Chemistry included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, etc. Urinalysis included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin and microscopy. Laboratory abnormalities were judged by the investigator. Laboratory abnormalities reported for at least 1 participant in the whole study are presented here.

    Time frame: From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days)

07

Results

Posted Oct 16, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1: Treatment A-> B-> C-> D-> ESequence 2: Treatment B-> D-> A-> C-> ESequence 3: Treatment C-> A-> D-> B-> ESequence 4: Treatment D-> C-> B-> A-> E
Started3333
Completed3333
Not completed0000
Period 2
Participant flow — Period 2
MilestoneSequence 1: Treatment A-> B-> C-> D-> ESequence 2: Treatment B-> D-> A-> C-> ESequence 3: Treatment C-> A-> D-> B-> ESequence 4: Treatment D-> C-> B-> A-> E
Started3333
Completed3333
Not completed0000
Period 3
Participant flow — Period 3
MilestoneSequence 1: Treatment A-> B-> C-> D-> ESequence 2: Treatment B-> D-> A-> C-> ESequence 3: Treatment C-> A-> D-> B-> ESequence 4: Treatment D-> C-> B-> A-> E
Started3333
Completed3333
Not completed0000
Period 4
Participant flow — Period 4
MilestoneSequence 1: Treatment A-> B-> C-> D-> ESequence 2: Treatment B-> D-> A-> C-> ESequence 3: Treatment C-> A-> D-> B-> ESequence 4: Treatment D-> C-> B-> A-> E
Started3333
Completed3333
Not completed0000
Period 5
Participant flow — Period 5
MilestoneSequence 1: Treatment A-> B-> C-> D-> ESequence 2: Treatment B-> D-> A-> C-> ESequence 3: Treatment C-> A-> D-> B-> ESequence 4: Treatment D-> C-> B-> A-> E
Started3333
Completed3232
Not completed0101
Withdrew: Not completing the meal0100
Withdrew: Adverse event0001

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib

AUCinf was defined as area under the plasma-concentration time profile from time zero extrapolated to infinite time. AUCinf for ritlecitinib was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose on Day 1 of each period. Each treatment period lasted 24 hours. Dosing of each period was separated by at least a 48-hour washout interval.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib
nanogram*hour per milliliter (ng*hr/mL)Ritlecitinib 30 mg Capsule (Fasted)Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted)Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted)Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted)Ritlecitinib 30 mg Capsule Given With High Fat Meal
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib389.1 ± 32398.3 ± 31378.0 ± 27387.8 ± 27387.0 ± 23
Statistical analysis
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) · Ratio (%) of adjusted geometric means: 102.36 · 90% CI 95.81 to 109.35
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) · Ratio (%) of adjusted geometric means: 97.15 · 90% CI 90.94 to 103.79
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) · Ratio (%) of adjusted geometric means: 99.65 · 90% CI 93.28 to 106.46
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Given With High Fat Meal · Ratio (%) of adjusted geometric means: 104.84 · 90% CI 97.30 to 112.96
PrimaryMaximum Observed Concentration (Cmax) of Ritlecitinib

Cmax was defined as maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose on Day 1 of each period. Each treatment period lasted 24 hours. Dosing of each period was separated by at least a 48-hour washout interval.
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of Ritlecitinib
ng/mLRitlecitinib 30 mg Capsule (Fasted)Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted)Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted)Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted)Ritlecitinib 30 mg Capsule Given With High Fat Meal
Maximum Observed Concentration (Cmax) of Ritlecitinib244.3 ± 35236.1 ± 28206.6 ± 24229.4 ± 25108.0 ± 28
Statistical analysis
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) · Ratio (%) of adjusted geometric means: 96.63 · 90% CI 83.66 to 111.62
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) · Ratio (%) of adjusted geometric means: 84.58 · 90% CI 73.23 to 97.70
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) · Ratio (%) of adjusted geometric means: 93.91 · 90% CI 81.30 to 108.48
  • Ritlecitinib 30 mg Capsule (Fasted) vs Ritlecitinib 30 mg Capsule Given With High Fat Meal · Ratio (%) of adjusted geometric means: 43.83 · 90% CI 37.50 to 51.23
SecondaryNumber of Participants With All-Causality and Treatment-Related Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were events between first dose of study treatment and up to approximately 35 days that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality and Treatment-Related Treatment Emergent Adverse Events (TEAEs)
ParticipantsRitlecitinib 30 mg Capsule (Fasted)Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted)Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted)Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted)Ritlecitinib 30 mg Capsule Given With High Fat Meal
Number of participants with all-causality TEAEs52442
Number of participants with all-causality SAEs00000
Number of participants with treatment-related TEAEs20101
Number of participants with treatment-related SAEs00000
SecondaryNumber of Participants With Laboratory Abnormalities

Hematology included hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet and white blood cell count, total neutrophils, eosinophils, etc. Chemistry included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, etc. Urinalysis included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin and microscopy. Laboratory abnormalities were judged by the investigator. Laboratory abnormalities reported for at least 1 participant in the whole study are presented here.

Time frame:
From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsRitlecitinib 30 mg Capsule (Fasted)Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted)Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted)Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted)Ritlecitinib 30 mg Capsule Given With High Fat Meal
Number of Participants With Laboratory Abnormalities00000

Adverse events

Collected over From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ritlecitinib 30 mg Capsule (Fasted)0/12 (0%)0/12 (0%)5/12 (41.7%)
Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted)0/12 (0%)0/12 (0%)2/12 (16.7%)
Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted)0/12 (0%)0/12 (0%)4/12 (33.3%)
Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted)0/12 (0%)0/12 (0%)4/12 (33.3%)
Ritlecitinib 30 mg Capsule Given With High Fat Meal0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventRitlecitinib 30 mg Capsule (Fasted)Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted)Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted)Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted)Ritlecitinib 30 mg Capsule Given With High Fat Meal
HaematomaVascular disorders1/121/122/124/120/10
AcneSkin and subcutaneous tissue disorders0/120/120/120/122/10
ToothacheGastrointestinal disorders0/120/120/120/121/10
Dry eyeEye disorders0/120/121/120/120/10
Abdominal discomfortGastrointestinal disorders1/120/120/120/120/10
Abdominal painGastrointestinal disorders0/120/121/120/120/10
DiarrhoeaGastrointestinal disorders0/120/121/120/120/10
Dry mouthGastrointestinal disorders1/120/120/120/120/10
Lip dryGastrointestinal disorders1/120/120/120/120/10
FatigueGeneral disorders1/120/120/120/120/10

Baseline characteristics

All participants who were enrolled in the study.

Age, Continuous
Age, Continuous(Years)All Participants
Mean40.4 ± 12.99
Age, Customized
Age, Customized(Participants)All Participants
26-35 years6
36-45 years3
>45 years3
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female4
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino1
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White8
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Jun 2023, 1 month.

Results were first posted in Oct 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 10, 2023
StartActual
May 9, 2023
Primary completionActual
Jun 15, 2023
CompletionActual
Jul 24, 2023
Results first posted
Oct 16, 2024
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05852340
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 10, 2023
Start date
May 9, 2023
Primary completion
Jun 15, 2023
Completion
Jul 24, 2023
Results posted
Oct 16, 2024
Last update
Oct 16, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion